InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,714.00
(
0.41%
)
Dow Jones
39,387.76
(
0.00%
)
Brent Oil
84.14
(
0.22%
)
Bitcoin
63,090.26
(
0.07%
)
Post# of 648882
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Tuff-Stuff

Send PM Follow Ignore
Followers 219
Posts 247348
Boards Moderated 2
Alias Born 04/06/2006

Tuff-Stuff

Re: EZ2 post# 544369

Tuesday, 09/09/2014 11:49:45 AM

Tuesday, September 09, 2014 11:49:45 AM

Post# of 648882
Still holding some> The FDA's Endocrinologic and Metabolic Drugs Advisory Committee meets this Thursday to discuss Novo Nordisk's (NVO +2.3%) NDA for Saxenda (liraglutide) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of at least 30 kg/m2 (or a BMI of 27 kg/m2 in the presence of at least one weight-related comorbidity).
Novo markets liraglutide injection as Victoza for the treatment of type 2 diabetes in conjunction with diet and exercise.
Briefing docs

Pray for A Pain Free Day!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up